Johnson & Johnson
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1886-01-01
- Employees
- 131.9K
- Market Cap
- $392.2B
- Website
- http://www.jnj.com
- Introduction
Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in the interventional solutions, orthopaedics, surgery, and vision categories. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1887 and is headquartered in New Brunswick, NJ.
The Role of Technology in Enhancing Diversity in Diabetes Clinical Trials
Technology enhances diversity in diabetes clinical trials by expanding outreach, simplifying participation, and improving data collection, leading to more inclusive and effective research outcomes.
Intravascular lithotripsy – a clinical trial snapshot
Intravascular lithotripsy (IVL) market is rapidly advancing, with Shockwave Medical's acquisition by Johnson & Johnson and recent catheter launch. Other companies like Amplitude Vascular Systems, Elixir Medical, FastWave Medical, and Bolt Medical are also progressing in clinical trials for their IVL technologies, focusing on safety and efficacy in treating calcified lesions.
J&J nets another key approval for blockbuster hope Rybrevant
Johnson & Johnson's Rybrevant (amivantamab) received FDA approval for use with chemotherapy in advanced NSCLC with EGFR exon 19 deletions or L858R mutations, following prior EGFR inhibitor treatment. The MARIPOSA-2 trial showed Rybrevant improved survival rates and progression-free survival compared to chemotherapy alone, though overall survival benefit was not yet statistically significant. Rybrevant aims to address resistance to third-generation EGFR inhibitors like AstraZeneca's Tagrisso.
DARZALEX® (daratumumab)-based quadruplet regimen receives positive CHMP opinion for ...
CHMP recommends daratumumab SC for newly diagnosed multiple myeloma eligible for ASCT, supported by PERSEUS study showing 60% reduction in risk of disease progression or death with quadruplet regimen.
RYBREVANT® (amivantamab-vmjw) plus standard of care approved in the U.S. as first and ...
FDA approves RYBREVANT® (amivantamab-vmjw) with chemotherapy for advanced EGFR-mutated NSCLC, based on MARIPOSA-2 study showing 52% reduced risk of disease progression.
Related Clinical Trials:
Johnson & Johnson Gets FDA Approval for Non-Small Cell Lung-Cancer Treatment
Johnson & Johnson's Rybrevant approved by FDA for treating locally-advanced or metastatic non-small cell lung cancer in combination with chemotherapy, reducing disease progression risk by 52%.
Rybrevant (amivantamab-vmjw) Plus Standard of Care Approved in the U.S. as First and Only Targeted Regimen to Cut Risk of Disease Progression by More Than Half in Second-Line EGFR-Mutated Advanced Lung Cancer
FDA approves Rybrevant (amivantamab-vmjw) plus chemotherapy for EGFR-mutated advanced NSCLC, reducing disease progression risk by 52%.
Related Clinical Trials:
Implantica's anti-reflux device shows positive two-year results
Implantica's RefluxStop device shows 90.9% improvement in quality of life for GORD patients, with 96.4% discontinuing PPI medication. The device reconstructs the anti-reflux barrier, unlike current methods, and is now seeking FDA approval.
Ins & Outs: C-suite rejigs at Regenxbio, Kyverna and Mirador
Kyverna appoints Warner Biddle as CEO, Christi Shaw to board. Regenxbio welcomes Mitchell Chan as CFO. Mirador Therapeutics appoints Gregg Gilbert as CFO.
Erythropoietin Drugs Market Estimated to Reach USD 14.3
The global erythropoietin drugs market is projected to grow at a CAGR of 3.8% from 2024 to 2034, reaching $14.3 billion by 2034. Advances in precision medicine, regulatory reforms for biosimilars, and telemedicine integration are driving market growth. Key players include Amgen, Roche, and Johnson & Johnson. Epoetin Alfa and biosimilars lead the market segments.
© Copyright 2025. All Rights Reserved by MedPath